|
Gene: CCT5 |
Gene summary for CCT5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CCT5 | Gene ID | 22948 |
Gene name | chaperonin containing TCP1 subunit 5 | |
Gene Alias | CCT-epsilon | |
Cytomap | 5p15.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B4DX08 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
22948 | CCT5 | GSM5353248_PA_PR5269_4_S28_L002 | Human | Prostate | Tumor | 4.63e-03 | -5.26e-02 | 0.1541 |
22948 | CCT5 | P1_S1_AK | Human | Skin | AK | 3.64e-04 | 2.83e-01 | -0.3399 |
22948 | CCT5 | P2_S3_AK | Human | Skin | AK | 2.18e-05 | 2.34e-01 | -0.3287 |
22948 | CCT5 | P4_S8_cSCC | Human | Skin | cSCC | 6.63e-14 | 3.87e-01 | -0.3095 |
22948 | CCT5 | P5_S10_cSCC | Human | Skin | cSCC | 5.62e-30 | 4.97e-01 | -0.299 |
22948 | CCT5 | P1_cSCC | Human | Skin | cSCC | 4.22e-47 | 1.90e+00 | 0.0292 |
22948 | CCT5 | P2_cSCC | Human | Skin | cSCC | 1.49e-42 | 1.61e+00 | -0.024 |
22948 | CCT5 | P4_cSCC | Human | Skin | cSCC | 9.51e-74 | 2.05e+00 | -0.00290000000000005 |
22948 | CCT5 | P10_cSCC | Human | Skin | cSCC | 1.89e-64 | 2.30e+00 | 0.1017 |
22948 | CCT5 | cSCC_p7 | Human | Skin | cSCC | 1.12e-02 | -1.92e-01 | -0.2332 |
22948 | CCT5 | cSCC_p8 | Human | Skin | cSCC | 5.21e-04 | 7.41e-06 | -0.1971 |
22948 | CCT5 | cSCC_p9 | Human | Skin | cSCC | 2.60e-03 | -2.97e-02 | -0.1991 |
22948 | CCT5 | Pat01-B | Human | Stomach | GC | 1.76e-14 | -4.30e-01 | 0.5754 |
22948 | CCT5 | Pat02-B | Human | Stomach | GC | 2.72e-38 | 1.69e-02 | 0.0368 |
22948 | CCT5 | Pat03-B | Human | Stomach | GC | 1.75e-19 | -2.19e-01 | 0.3693 |
22948 | CCT5 | Pat04-B | Human | Stomach | GC | 8.55e-24 | -3.41e-02 | -0.1483 |
22948 | CCT5 | Pat05-B | Human | Stomach | GC | 6.60e-07 | -2.41e-01 | -0.0353 |
22948 | CCT5 | Pat06-B | Human | Stomach | GC | 2.60e-47 | 1.10e-02 | -0.1961 |
22948 | CCT5 | Pat09-B | Human | Stomach | GC | 5.71e-08 | -1.23e-01 | -0.0359 |
22948 | CCT5 | Pat11-B | Human | Stomach | GC | 1.52e-10 | 5.89e-03 | -0.182 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064578 | Breast | Precancer | protein folding | 43/1080 | 212/18723 | 3.48e-13 | 7.45e-11 | 43 |
GO:00508219 | Breast | Precancer | protein stabilization | 29/1080 | 191/18723 | 1.67e-06 | 6.08e-05 | 29 |
GO:00316479 | Breast | Precancer | regulation of protein stability | 38/1080 | 298/18723 | 3.73e-06 | 1.19e-04 | 38 |
GO:00108338 | Breast | Precancer | telomere maintenance via telomere lengthening | 15/1080 | 81/18723 | 5.31e-05 | 1.11e-03 | 15 |
GO:00007238 | Breast | Precancer | telomere maintenance | 20/1080 | 131/18723 | 6.10e-05 | 1.25e-03 | 20 |
GO:19901734 | Breast | Precancer | protein localization to nucleoplasm | 6/1080 | 14/18723 | 7.30e-05 | 1.44e-03 | 6 |
GO:20005738 | Breast | Precancer | positive regulation of DNA biosynthetic process | 13/1080 | 66/18723 | 8.54e-05 | 1.63e-03 | 13 |
GO:19049519 | Breast | Precancer | positive regulation of establishment of protein localization | 36/1080 | 319/18723 | 9.30e-05 | 1.75e-03 | 36 |
GO:19048743 | Breast | Precancer | positive regulation of telomerase RNA localization to Cajal body | 6/1080 | 15/18723 | 1.16e-04 | 2.08e-03 | 6 |
GO:19048516 | Breast | Precancer | positive regulation of establishment of protein localization to telomere | 5/1080 | 10/18723 | 1.25e-04 | 2.21e-03 | 5 |
GO:00070047 | Breast | Precancer | telomere maintenance via telomerase | 13/1080 | 69/18723 | 1.37e-04 | 2.38e-03 | 13 |
GO:19043567 | Breast | Precancer | regulation of telomere maintenance via telomere lengthening | 12/1080 | 61/18723 | 1.61e-04 | 2.69e-03 | 12 |
GO:19043588 | Breast | Precancer | positive regulation of telomere maintenance via telomere lengthening | 9/1080 | 37/18723 | 1.96e-04 | 3.10e-03 | 9 |
GO:00702034 | Breast | Precancer | regulation of establishment of protein localization to telomere | 5/1080 | 11/18723 | 2.18e-04 | 3.35e-03 | 5 |
GO:19048694 | Breast | Precancer | regulation of protein localization to Cajal body | 5/1080 | 11/18723 | 2.18e-04 | 3.35e-03 | 5 |
GO:19048714 | Breast | Precancer | positive regulation of protein localization to Cajal body | 5/1080 | 11/18723 | 2.18e-04 | 3.35e-03 | 5 |
GO:00062786 | Breast | Precancer | RNA-dependent DNA biosynthetic process | 13/1080 | 75/18723 | 3.27e-04 | 4.64e-03 | 13 |
GO:0035036 | Breast | Precancer | sperm-egg recognition | 10/1080 | 48/18723 | 3.43e-04 | 4.81e-03 | 10 |
GO:00702026 | Breast | Precancer | regulation of establishment of protein localization to chromosome | 5/1080 | 12/18723 | 3.56e-04 | 4.93e-03 | 5 |
GO:19034053 | Breast | Precancer | protein localization to nuclear body | 5/1080 | 12/18723 | 3.56e-04 | 4.93e-03 | 5 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCT5 | SNV | Missense_Mutation | rs762786367 | c.1046N>T | p.Thr349Ile | p.T349I | P48643 | protein_coding | deleterious(0) | possibly_damaging(0.71) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
CCT5 | SNV | Missense_Mutation | c.1031G>T | p.Arg344Met | p.R344M | P48643 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CCT5 | SNV | Missense_Mutation | c.1018C>T | p.Arg340Trp | p.R340W | P48643 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CCT5 | SNV | Missense_Mutation | c.1018N>T | p.Arg340Trp | p.R340W | P48643 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
CCT5 | SNV | Missense_Mutation | rs768768696 | c.1006G>A | p.Ala336Thr | p.A336T | P48643 | protein_coding | tolerated(0.07) | benign(0.325) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCT5 | SNV | Missense_Mutation | novel | c.359N>T | p.Ala120Val | p.A120V | P48643 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CCT5 | SNV | Missense_Mutation | rs768768696 | c.1006N>A | p.Ala336Thr | p.A336T | P48643 | protein_coding | tolerated(0.07) | benign(0.325) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CCT5 | SNV | Missense_Mutation | c.338N>A | p.Ala113Asp | p.A113D | P48643 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
CCT5 | SNV | Missense_Mutation | novel | c.819N>G | p.Asp273Glu | p.D273E | P48643 | protein_coding | tolerated(1) | benign(0.019) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CCT5 | SNV | Missense_Mutation | c.1400N>A | p.Gly467Asp | p.G467D | P48643 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |